RG
DFTX

Rathbones Group’s Definium Therapeutics DFTX Stock Holding History

Rathbones Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$571K Hold
30,200
– – ﹤0.01% 437
2025
Q4 		$404K Hold
30,200
– – ﹤0.01% 482
2025
Q3 		$356K Buy
30,200
+2,000
+7% +$18.7K ﹤0.01% 493
2025
Q2 		$183K Hold
28,200
– – ﹤0.01% 564
2025
Q1 		$165K Buy
28,200
+8,000
+40% +$57.3K ﹤0.01% 543
2024
Q4 		$141K Hold
20,200
– – ﹤0.01% 554
2024
Q3 		$115K Sell
20,200
-4,000
-17% -$27.8K ﹤0.01% 559
2024
Q2 		$174K Hold
24,200
– – ﹤0.01% 556
2024
Q1 		$227K Sell
24,200
-800
-3% -$4.56K ﹤0.01% 533
2023
Q4 		$91.5K Hold
25,000
– – ﹤0.01% 567
2023
Q3 		$78.3K Buy
+25,000
New +$103K ﹤0.01% 580

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rathbones Group's DFTX Position: Q1 2026 in Review

Rathbones Group held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 30,200 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #437.

Rathbones Group first reported a position in DFTX in Q3 2023 and has held it in 11 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Rathbones Group held 30,200 shares of Definium Therapeutics worth $571K as of Q1 2026.
  • Rathbones Group left its Definium Therapeutics share count unchanged in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #437 holding.
  • Rathbones Group first reported a position in Definium Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.